BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
Rhea-AI Summary
BeiGene, a biotechnology company, will host an investor conference call on May 29, 2020, at 8:00 p.m. ET to discuss clinical study results from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. This event will be accessible via a live webcast on BeiGene's investor website, with a replay available for 90 days. BeiGene is focused on developing innovative cancer treatments and currently markets two oncology products: BRUKINSA™ and tislelizumab, with additional oncology products planned for the Chinese market.
Positive
- Upcoming investor conference call to discuss clinical study results
- Live webcast available for investor engagement
- Two marketed oncology products: BRUKINSA™ and tislelizumab
Negative
- None.
News Market Reaction – BGNE
On the day this news was published, BGNE declined 1.82%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 (GLOBE NEWSWIRE) -- CAMBRIDGE, Mass. and BEIJING, China, May 22, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will host an investor conference call and webcast on Friday, May 29, 2020 at 8:00 p.m. ET to discuss clinical study results presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com
Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com
FAQ
What is the date and time of BeiGene's investor conference call?
How can I access the BeiGene investor conference call?
What will be discussed during the conference call?
What oncology products does BeiGene currently market?
